community download

Case study: outsourcing Recombinant DNA and MVA vaccine manufacturing

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

 
In 2010, 34 million people were living with HIV with 2.7 million new cases. 1.8 million AIDS-related deaths were recorded in 2010 alone, and 6.6 million people were receiving Antiretroviral Therapy. GeoVax DNA/MVA HIV vaccine, currently in development, brings hope to the possibility of an HIV vaccine.
 
Michael Hellerstein, Director, Quality Control, GeoVax Inc., joined us at the World Vaccine Manufacturing Congress, part of the World Vaccine Congress in Washington 2012 to update the industry on the development of the DNA/MVA HIV vaccine, which is now in Phase 2 of clinical trials and the problems and lessons learnt from outsourcing.
 
If you are currently researching, working or hoping to outsource vaccine manufacturing, this case study is well worth a read. Why not download the full presentation and discover more about vaccine manufacturing and the lessons learnt by GeoVax!